UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Oral antiseptics against coronavirus: in-vitro and clinical evidence

The Journal of hospital infection, 2021-07, Vol.113, p.30-43

2021

Volltextzugriff (PDF)

P29 PHASE 1/2 RESULTS OF TALQUETAMAB, A G PROTEIN‐COUPLED RECEPTOR FAMILY C GROUP 5 MEMBER D X CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) (MONUMENTAL‐1)

HemaSphere, 2023-05, Vol.7 (S2), p.26-27

2023

Volltextzugriff (PDF)

Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Annals of oncology, 2021-03, Vol.32 (3), p.309-322

2021

Volltextzugriff (PDF)

PSY7 Budget Impact Analysis of Bendamustine in the Treatment of Multiple Myeloma in Spain

Value in health, 2011, Vol.14 (7), p.A411-A411

2011

Volltextzugriff (PDF)

MC13-0007 Metabolomic profile of multiple myeloma patients

European journal of cancer (1990), 2013-11, Vol.49, p.S14-S14

2013

Volltextzugriff (PDF)

Challenges and Solutions with First-generation Proteasome Inhibition: Practical Strategies

Clinical lymphoma, myeloma and leukemia, 2015-09, Vol.15, p.e13-e13

2015

Volltextzugriff (PDF)

Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Annals of oncology, 2017-07, Vol.28 (suppl_4), p.iv52-iv61

2017

Volltextzugriff (PDF)

Inverse Probability of Censoring Weighted Analysis to Adjust the Treatment Effect on Overall Survival for Subsequent Therapy: A Case Study in a Clinical Trial in Multiple Myeloma

Value in health, 2014-11, Vol.17 (7), p.A546-A546

2014

Volltextzugriff (PDF)

Amiloride induces potent antitumoral activity in multiple myeloma through the reactivation of mutant p53

Clinical lymphoma, myeloma and leukemia, 2015-09, Vol.15, p.e251-e251

2015

Volltextzugriff (PDF)

Bortezomib in multiple myeloma

Best practice & research. Clinical haematology, 2007-12, Vol.20 (4), p.701-715

2007

Volltextzugriff (PDF)

Flow Cytometry for Minimal Residual Disease

Clinical lymphoma, myeloma and leukemia, 2015-09, Vol.15, p.e5-e5

2015

Volltextzugriff (PDF)

Treatment of renal failure in patients with newly diagnosed multiple mieloma with bortezomib and dexamethasone: results of a phase II trial from PETHEMA/GEM group (RENVEL)

Clinical lymphoma, myeloma and leukemia, 2015-09, Vol.15, p.e256-e257

2015

Volltextzugriff (PDF)

Filanesib (ARRY-520) Demonstrates Potent and Rapid Activity in Preclinical Models of MM, Dependent on Bcl-2 Family Expression, and Synergistic with Dexamethasone and IMiDs

Clinical lymphoma, myeloma and leukemia, 2015-09, Vol.15, p.e213-e214

2015

Volltextzugriff (PDF)

Preclinical Antimyeloma Activity of EDO-S101

Clinical lymphoma, myeloma and leukemia, 2015-09, Vol.15, p.e218-e218

2015

Volltextzugriff (PDF)

Outcome of Patients with Extramedullary Plasmacytomas (EMPs) Included in a Phase III PETHEMA/GEM Study of Induction Therapy Prior Autologous Stem Cell Transplantation (ASCT) in Multiple Myeloma (MM)

Clinical lymphoma, myeloma and leukemia, 2015-09, Vol.15, p.e100-e100

2015

Volltextzugriff (PDF)

Two randomized open-label studies of daratumumab (DARA) plus standard of care treatment versus standard of care alone in patients with previously untreated multiple myeloma (MM) ineligible for high-dose therapy: 54767414MMY3007 (Alcyone) and 54767414MMY3008 (Maia)

Clinical lymphoma, myeloma and leukemia, 2015-09, Vol.15, p.e294-e295

2015

Volltextzugriff (PDF)

Dexamethasone as a partner of isatuximab

Blood, 2021-03, Vol.137 (9), p.1133-1134

2021

Volltextzugriff (PDF)

Pretransplant induction with VTD (Bortezomib/Thalidomide/Dexamethasone) significantly improves PFS: long-term results of the randomized phase 3 PETHEMA/GEM study

Clinical lymphoma, myeloma and leukemia, 2015-09, Vol.15, p.e49-e50

2015

Volltextzugriff (PDF)

Subcutaneous Bortezomib Plus Melphalan and Prednisone (VMP) in Non-Transplant Eligible Newly Diagnosed Multiple Myeloma (MM) Patients: Spanish Experience

Clinical lymphoma, myeloma and leukemia, 2015-09, Vol.15, p.e135-e136

2015

Volltextzugriff (PDF)

Immunoparesis Recovery as Predictor Marker of Progression After Autologous Stem Cell Transplantation in Multiple Myeloma

Clinical lymphoma, myeloma and leukemia, 2015-09, Vol.15, p.S51-S51

2015

Volltextzugriff (PDF)

Frontline therapy for multiple myeloma (MM) in real-world clinical practice: Results from the third interim analysis of the multinational, non-interventional, observational EMMOS study

Clinical lymphoma, myeloma and leukemia, 2015-09, Vol.15, p.e127-e128

2015

Volltextzugriff (PDF)

EE73 Ocean (OP-103): Patients with Relapsed/Refractory Multiple Myeloma Treated with Melflufen Plus Dexamethasone or Pomalidomide Plus Dexamethasone - a Resource Utilization Analysis of Adverse Events Leading to Hospitalizations

Value in health, 2023-12, Vol.26 (12), p.S64

2023

Volltextzugriff (PDF)

HPR9 Value Criteria for Outcomes Based Managed Entry Agreement of CAR-T in Relapsed or Refractory Multiple Myeloma (RRMM) through MCDA

Value in health, 2023-12, Vol.26 (12), p.S256

2023

Volltextzugriff (PDF)

Expert panel consensus statement on the optimal use of pomalidomide in relapsed and refractory multiple myeloma

Leukemia, 2014-08, Vol.28 (8), p.1573-1585

2014

Volltextzugriff (PDF)

Critical evaluation of ASO RQ-PCR for minimal residual disease evaluation in multiple myeloma. A comparative analysis with flow cytometry

Leukemia, 2014-02, Vol.28 (2), p.391-397

2014

Volltextzugriff (PDF)

1 – 25 von 98

Suche als RSS-Feed

Aktive Filter

ThemaAnimals

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(87)
Mit Volltextzugriff
(94)

Publikationsform

Artikel
(96)
Tagungsberichte
(2)

Sprache

Englisch
(83)
Spanisch
(15)

Erscheinungsjahr

n.n

Thema

Science & Technology
(25)
Life Sciences & Biomedicine
(21)
Hematology, Oncology And Palliative Medicine
(18)
Humans
(15)
Multiple Myeloma
(10)
Oncology
(9)
Hematology
(8)
Internal Medicine
(7)
Male
(7)
Middle Aged
(7)
Adult
(6)
Biological And Medical Sciences
(6)
Care And Treatment
(6)
Female
(6)
Medical Sciences
(5)
Patients
(5)
Spain
(5)
Stem Cells
(5)
Transplantation
(5)
Agriculture
(4)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Oral antiseptics against coronavirus: in-vitro and clinical evidence

P29 PHASE 1/2 RESULTS OF TALQUETAMAB, A G PROTEIN‐COUPLED RECEPTOR FAMILY C GROUP 5 MEMBER D X CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) (MONUMENTAL‐1)

Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

PSY7 Budget Impact Analysis of Bendamustine in the Treatment of Multiple Myeloma in Spain

MC13-0007 Metabolomic profile of multiple myeloma patients

Challenges and Solutions with First-generation Proteasome Inhibition: Practical Strategies

Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Inverse Probability of Censoring Weighted Analysis to Adjust the Treatment Effect on Overall Survival for Subsequent Therapy: A Case Study in a Clinical Trial in Multiple Myeloma

Amiloride induces potent antitumoral activity in multiple myeloma through the reactivation of mutant p53

Bortezomib in multiple myeloma

Flow Cytometry for Minimal Residual Disease

Treatment of renal failure in patients with newly diagnosed multiple mieloma with bortezomib and dexamethasone: results of a phase II trial from PETHEMA/GEM group (RENVEL)

Filanesib (ARRY-520) Demonstrates Potent and Rapid Activity in Preclinical Models of MM, Dependent on Bcl-2 Family Expression, and Synergistic with Dexamethasone and IMiDs

Preclinical Antimyeloma Activity of EDO-S101

Outcome of Patients with Extramedullary Plasmacytomas (EMPs) Included in a Phase III PETHEMA/GEM Study of Induction Therapy Prior Autologous Stem Cell Transplantation (ASCT) in Multiple Myeloma (MM)

Two randomized open-label studies of daratumumab (DARA) plus standard of care treatment versus standard of care alone in patients with previously untreated multiple myeloma (MM) ineligible for high-dose therapy: 54767414MMY3007 (Alcyone) and 54767414MMY3008 (Maia)

Dexamethasone as a partner of isatuximab

Pretransplant induction with VTD (Bortezomib/Thalidomide/Dexamethasone) significantly improves PFS: long-term results of the randomized phase 3 PETHEMA/GEM study

Subcutaneous Bortezomib Plus Melphalan and Prednisone (VMP) in Non-Transplant Eligible Newly Diagnosed Multiple Myeloma (MM) Patients: Spanish Experience

Immunoparesis Recovery as Predictor Marker of Progression After Autologous Stem Cell Transplantation in Multiple Myeloma

Frontline therapy for multiple myeloma (MM) in real-world clinical practice: Results from the third interim analysis of the multinational, non-interventional, observational EMMOS study

EE73 Ocean (OP-103): Patients with Relapsed/Refractory Multiple Myeloma Treated with Melflufen Plus Dexamethasone or Pomalidomide Plus Dexamethasone - a Resource Utilization Analysis of Adverse Events Leading to Hospitalizations

HPR9 Value Criteria for Outcomes Based Managed Entry Agreement of CAR-T in Relapsed or Refractory Multiple Myeloma (RRMM) through MCDA

Expert panel consensus statement on the optimal use of pomalidomide in relapsed and refractory multiple myeloma

Critical evaluation of ASO RQ-PCR for minimal residual disease evaluation in multiple myeloma. A comparative analysis with flow cytometry

Aktive Filter

Suchergebnisse filtern